Overactive Bladder
Oxybutynin-Associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment - Beyond the Abstract
July 23, 2024
Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights from AUA Quality Registry - Beyond the Abstract
February 7, 2024
Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA - Beyond the Abstract
March 20, 2023
The Choice of Therapeutic Agent in Female Overactive Bladder Patients in Real-World Practice - Beyond the Abstract
February 22, 2023
Urobiome Changes Differ Based on OAB Treatment in Adult Females - Beyond the Abstract
January 17, 2023
A Systematic Review and In Silico Study of Potential Genetic Markers Implicated in Cases of Overactive Bladder - Beyond the Abstract
September 29, 2022